RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+25.77%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$4.05B
AUM Growth
+$4.05B
(+8.5%)
Cap. Flow
-$190M
Cap. Flow
% of AUM
-4.69%
Top 10 Holdings %
Top 10 Hldgs %
37.5%
Holding
124
New
3
Increased
35
Reduced
29
Closed
20
Top Buys
| 1 |
Eli Lilly
LLY
|
$40.5M |
| 2 |
Celldex Therapeutics
CLDX
|
$18.6M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$18.1M |
| 4 |
Immunovant
IMVT
|
$14.3M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$13.3M |
Top Sells
Sector Composition
| 1 | Healthcare | 97.34% |
| 2 | Consumer Staples | 1.42% |
| 3 | Industrials | 1.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Edwards Lifesciences
EW
$47.8B
| $49.4M | 1.22% | 647,300 | – | – |
|
|
MRTX
27
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $49.1M | 1.21% | 835,776 -295,431 | -26% | -$17.4M |
|
28
West Pharmaceutical
WST
$17.8B
| $48.3M | 1.19% | 137,250 -64,750 | -32% | -$22.8M |
|
29
Agios Pharmaceuticals
AGIO
$2.19B
| $47.9M | 1.18% | 2,152,173 -557,888 | -21% | -$12.4M |
|
30
Madrigal Pharmaceuticals
MDGL
$9.76B
| $45.9M | 1.13% | 198,169 +1,800 | +0.9% | +$416K |
|
31
Alnylam Pharmaceuticals
ALNY
$58.5B
| $45M | 1.11% | 235,000 -44,500 | -16% | -$8.52M |
|
|
OLK
32
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $42.2M | 1.04% | 1,676,500 | – | – |
|
|
ACCD
33
DELISTED
Accolade, Inc. Common Stock
ACCD
| $41.9M | 1.03% | 3,485,000 +572,000 | +20% | +$6.87M |
|
|
34
Immunovant
IMVT
$2.56B
| $41.4M | 1.02% | 983,301 +338,957 | +53% | +$14.3M |
|
|
35
Eli Lilly
LLY
$657B
| $40.5M | 1% | +69,500 | New | +$40.5M |
|
36
Kymera Therapeutics
KYMR
$2.95B
| $38.8M | 0.95% | 1,522,238 +17,887 | +1% | +$455K |
|
|
37
Celldex Therapeutics
CLDX
$1.47B
| $38.5M | 0.95% | 969,646 +469,545 | +94% | +$18.6M |
|
38
iRhythm Technologies
IRTC
$5.46B
| $37.5M | 0.92% | 350,750 | – | – |
|
39
Ascendis Pharma
ASND
$11.8B
| $36.5M | 0.9% | 290,000 -135,500 | -32% | -$17.1M |
|
40
Pacira BioSciences
PCRX
$1.2B
| $35.6M | 0.88% | 1,055,500 | – | – |
|
41
Lifestance Health
LFST
$2.13B
| $35.5M | 0.87% | 4,535,000 +865,000 | +24% | +$6.77M |
|
42
Azenta
AZTA
$1.4B
| $33.1M | 0.81% | 507,500 +30,000 | +6% | +$1.95M |
|
43
Sarepta Therapeutics
SRPT
$1.78B
| $31.6M | 0.78% | 327,600 -64,400 | -16% | -$6.21M |
|
44
Zai Lab
ZLAB
$3.68B
| $31.1M | 0.77% | 1,137,023 -100,000 | -8% | -$2.73M |
|
45
Legend Biotech
LEGN
$6.41B
| $29.6M | 0.73% | 492,444 +34,179 | +7% | +$2.06M |
|
46
Warby Parker
WRBY
$3.2B
| $28.6M | 0.7% | 2,028,300 +453,300 | +29% | +$6.39M |
|
47
Akero Therapeutics
AKRO
$3.74B
| $25.2M | 0.62% | 1,081,064 -338,086 | -24% | -$7.89M |
|
48
Travere Therapeutics
TVTX
$1.56B
| $24.9M | 0.61% | 2,771,446 +963,704 | +53% | +$8.66M |
|
49
Merus
MRUS
$4.98B
| $24M | 0.59% | 872,069 +33,641 | +4% | +$925K |
|
50
Dynavax Technologies
DVAX
$1.19B
| $23.4M | 0.58% | 1,675,474 -138,284 | -8% | -$1.93M |
|